| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 219.22 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Introduction: Acetyl-L-Carnitine (ALC) has been proposed to have beneficial effects in
chronic neurodegenerative disorders caused by production of abnormal proteins,
mitochondrial dysfunction and oxidative stress. Recently, our group demonstrated that
pre-treatment with ALC confers effective neuroprotection against 3,4-
methylenedioximethamphetamine (MDMA)-induced neurotoxicity. These pre-clinical
studies reinforce the beneficial potential of ALC as a neuroprotectant in
neurodegenerative disorders. However, little is known about the molecular
mechanisms underlying ALC action.